Quintrio
Home

Stock overview

Virax Biolabs Group Limited Ordinary Shares

VRAX

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Last trade $0.43
Day change -$0.018 (-4.02%)
Day range $0.415 – $0.471
Volume 105,459
Market cap $1M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for VRAX.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for VRAX.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes

Virax Biolabs Group Limited announced positive early pilot data for ViraxImmune™, a blood-based diagnostic test for Long COVID and related post-acute infection syndromes. The test demonstrated 88% specificity and 92% positive predictive value in separating PAIS patients from healthy controls across 120+ subjects. The company plans a larger clinical validation study with 300 additional participants, with analysis expected in Q4 2026 and results in Q1 2027, targeting a U.S. Laboratory Developed Test market entry.

Benzinga

Virax Biolabs Group Limited Announces $5 Million Private Placement

Virax Biolabs Group Limited has entered into agreements for a private placement of 12,500,000 ordinary shares and preferred investment options at $0.40 per share, expecting to raise $5 million for working capital and corporate purposes.

Benzinga

Why LQR House Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket

Shares of LQR House Inc. (NASDAQ: LQR) rose sharply in pre-market trading. Borg's investor group has acquired a 20% stake in LQR House. LQR House shares jumped 16.1% to $4.25 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares rose 64% to $2.28 in pre-market trading after gaining over 13% on Friday. Phunware, Inc. (NASDAQ: PHUN) shares jumped 34.5% to $0.1021 in pre-market trading. MorphoSys AG (NASDAQ: MOR) gained 18.8% to $10.21 in pre-market trading. Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 13.6% to $1.17 in pre-market trading after falling more than 6% on Friday. U Power Limited (NASDAQ: UCAR) shares gained 12.7% to $0.1459 in pre-market trading. WISeKey International Holding AG (NASDAQ: WKEY) gained 11.8% to $2.87 in pre-market trading. SEALSQ launched SEALCOIN.AI in partnership with Google Cloud. Agenus Inc. (NASDAQ: ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 14, 20261-for-4reverse split
Jun 26, 20261-for-25reverse split
Dec 18, 20231-for-10reverse split